News

Narcan Nasal Spray has been granted Fast Track Designation by the FDA. Narcan Nasal Spray was developed in collaboration with the National Institutes on Drug Abuse (NIDA). There

The core expertise of PRC Clinical is focused on Clinical Trial Management, Clinical Site Monitoring, and Clinical Payment Services. The CSSi LifeSciences and PRC Clinical partnership equips both

"Important goals of pharmacotherapy for ulcerative colitis are to induce and maintain remission while improving the patient’s quality of life, and, based on the results from our Phase

Roxane is a well-established US specialty generics company with a highly differentiated product portfolio and best-in-class R&D capabilities. Under the terms of the acquisition, on closing of the

ZS-9 is an insoluble, non-absorbed zirconium silicate with a three-dimensional crystalline lattice structure that was designed to preferentially trap potassium ions. The potassium selectivity of ZS-9 allows high

The breakthrough status was based on the results from a Phase II clinical trial (Study 205) of lenvatinib in advanced or metastatic renal cell carcinoma following one prior

The multicenter, open-label treatment-optimized, double-blind, randomized, placebo-controlled, forced-withdrawal, parallel group Phase III trial is expected to generate top-line data by year-end. HLD200 is a new delayed and extended

In the NDA, OPKO seeks approval of Rayaldee for the prevention and treatment of secondary hyperparathyroidism (SHPT) in patients with stage 3 or 4 chronic kidney disease (CKD)

Under terms of the agreement, Merck, through a subsidiary, will acquire all outstanding stock of cCAM in exchange for an upfront payment of $95 million in cash. In